James Galvin
James Galvin
Professor of Neurology, University of Miami Miller School of Medicine
Verified email at
Cited by
Cited by
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium
IG McKeith, DW Dickson, J Lowe, M Emre, JT O'brien, H Feldman, ...
Neurology 65 (12), 1863-1872, 2005
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
IG McKeith, BF Boeve, DW Dickson, G Halliday, JP Taylor, D Weintraub, ...
Neurology 89 (1), 88-100, 2017
The AD8: a brief informant interview to detect dementia
JE Galvin, CM Roe, KK Powlishta, MA Coats, SJ Muich, E Grant, JP Miller, ...
Neurology 65 (4), 559-564, 2005
Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis
Y Iturria-Medina, RC Sotero, PJ Toussaint, JM Mateos-Pérez, AC Evans
Nature communications 7 (1), 11934, 2016
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial
JF Quinn, R Raman, RG Thomas, K Yurko-Mauro, EB Nelson, C Van Dyck, ...
Jama 304 (17), 1903-1911, 2010
Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α‐synuclein
P Tu, JE Galvin, M Baba, B Giasson, T Tomita, S Leight, S Nakajo, ...
Annals of neurology 44 (3), 415-422, 1998
Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease
HI Hurtig, JQ Trojanowski, J Galvin, D Ewbank, ML Schmidt, VMY Lee, ...
Neurology 54 (10), 1916-1921, 2000
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers
CF Lippa, JE Duda, M Grossman, HI Hurtig, D Aarsland, BF Boeve, ...
Neurology 68 (11), 812-819, 2007
Synucleinopathies: clinical and pathological implications
JE Galvin, VMY Lee, JQ Trojanowski
Archives of neurology 58 (2), 186-190, 2001
Axon pathology in Parkinson’s disease and Lewy body dementia hippocampus contains α-, β-, and γ-synuclein
JE Galvin, K Uryu, VMY Lee, JQ Trojanowski
Proceedings of the National Academy of Sciences 96 (23), 13450-13455, 1999
Validity and reliability of the AD8 informant interview in dementia
JE Galvin, CM Roe, C Xiong, JC Morris
Neurology 67 (11), 1942-1948, 2006
Research criteria for the diagnosis of prodromal dementia with Lewy bodies
IG McKeith, TJ Ferman, AJ Thomas, F Blanc, BF Boeve, H Fujishiro, ...
Neurology 94 (17), 743-755, 2020
Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease
AS Fleisher, R Raman, ER Siemers, L Becerra, CM Clark, RA Dean, ...
Archives of neurology 65 (8), 1031-1038, 2008
Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease
ER Siemers, JF Quinn, J Kaye, MR Farlow, A Porsteinsson, P Tariot, ...
Neurology 66 (4), 602-604, 2006
Distinguishing Alzheimer’s disease from other major forms of dementia
S Karantzoulis, JE Galvin
Expert review of neurotherapeutics 11 (11), 1579-1591, 2011
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
M Sano, KL Bell, D Galasko, JE Galvin, RG Thomas, CH Van Dyck, ...
Neurology 77 (6), 556-563, 2011
Longitudinal study of the transition from healthy aging to Alzheimer disease
DK Johnson, M Storandt, JC Morris, JE Galvin
Archives of neurology 66 (10), 1254-1259, 2009
Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE
S Ayton, NG Faux, AI Bush
Nature communications 6 (1), 6760, 2015
Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease
MM Williams, C Xiong, JC Morris, JE Galvin
Neurology 67 (11), 1935-1941, 2006
Clinical phenotype of Parkinson disease dementia
JE Galvin, J Pollack, JC Morris
Neurology 67 (9), 1605-1611, 2006
The system can't perform the operation now. Try again later.
Articles 1–20